Dex in the Jail: Medetomidine Worsens Opioid Withdrawals Behind Bars
Medetomidine, an adulterant now found in illicit fentanyl, is triggering severe, fast-onset opioid withdrawal in incarcerated people and often requires complex treatment beyond standard detox, including higher-dose clonidine and hospital-level care. Jails with established MOUD programs fare better, but many facilities lack resources, detection can be difficult, and political/funding barriers remain. Cases from Pennsylvania show life-threatening complications and death, underscoring the need for broader access to addiction medicines and prompt hospital referrals to safely manage medetomidine withdrawal.